Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

Moderna, Inc. (MRNA) reported a loss of $3.33 per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $3.47. In the year-ago period, management posted a loss of $3.62. Revenues in the quarter were $241 million, beating the Zacks Consensus Estimate of $124.9 million. Total revenues declined 30% year over year due to reduced COVID-19 vaccine sales during the quarter. Quarter in Detail Product sales, entirely from the sale of COVID-19 vaccines, were down 37% year over year to ...